Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France

(2019) Ludivine Demessine et al.   Open Forum Infectious Diseases

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

(2019) Hanh Thi Pham et al.   EXPERT OPINION ON PHARMACOTHERAPY

Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks

(2019) Rima K. Acosta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) Hans-Jürgen Stellbrink et al.   Lancet HIV

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) David A Wohl et al.   Lancet HIV

Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a population-based study

(2019) Beatriz López-Centeno et al.   CLINICAL INFECTIOUS DISEASES

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

(2019) Kristen Andreatta et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women

(2019) Cissy Kityo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Weight gain and integrase inhibitors

(2019) Allison Ross Eckard et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide

(2018) Anthony T. Podany et al.   AIDS

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients

(2018) Clotilde Allavena et al.   PLoS One

Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection

(2018) Emma D. Deeks   DRUGS

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

(2017) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

(2017) Adam Trickey et al.   Lancet HIV

Sex, Age, Race and Intervention Type in Clinical Studies of HIV Cure: A Systematic Review

(2015) Rowena E. Johnston et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Increasing trends in HIV prevalence among people aged 50 years and older

(2014) Mary Mahy et al.   AIDS

Evaluation of the Effect of Cobicistat on theIn VitroRenal Transport and Cytotoxicity Potential of Tenofovir

(2013) Kirsten M. Stray et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Virologic and immunologic response to HAART, by age and regimen class

(2010) Keri N Althoff et al.   AIDS